HTA ID Drug Brand Indication Assessment status Date
20038 Delafloxacin Quofenix® For the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Rapid review complete 19th November 2020
- Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD Sativex® Indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy. NCPE Assessment Process Complete 20th October 2023
- Denosumab Prolia® For the Prevention of Osteoporotic Fractures in Postmenopausal Women NCPE Assessment Process Complete 1st July 2010
- Denosumab Xgeva® For the prevention of skeletal related events in adults with bone metastases from solid tumours in Ireland NCPE Assessment Process Complete 8th December 2011
23030 Deucravacitinib Sotyktu® Deucravacitinib is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Rapid Review Complete 14th March 2024
- Dexamethasone Intravitreal Implant Ozurdex® Treatment of macular oedema following Retinal Vein Occlusion NCPE Assessment Process Complete 16th March 2012
- Dexmedetomidine Dexdor® For the treatment of ICU adult patients requiring light to moderate sedation Rapid Review Complete 6th September 2011
- Diclofenac Itami® For the local symptomatic and short-term treatment (max. 7 days) of pain in acute strains, sprains or bruises of the extremities following blunt trauma e.g. sports injuries in adolescents aged from 16 years and adults Rapid Review Complete 17th January 2019
- Dienogest Visanne® For the Treatment of Endometriosis Rapid Review Complete 4th October 2010
23001 Difelikefalin Kapruvia® For the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis. NCPE Assessment Process Complete 6th February 2024
- Dimethyl fumarate Skilarence® For the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy. Rapid Review Complete 6th February 2018
- Dimethyl fumarate Tecfidera® For the treatment of adult patients with relapsing remitting multiple sclerosis (MS) NCPE Assessment Process Complete 16th January 2015
__ Dinutuximab beta Qarziba® For the treatment of high-risk neuroblastoma in patients ≥ 12 months, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed/refractory neuroblastoma, with or without residual disease. NCPE Assessment Process Complete 22nd October 2018
21047 Diroximel fumarate Vumerity® For the treatment of adult patients with relapsing-remitting multiple sclerosis Rapid Review Complete 16th December 2021
- Dolutegravir Tivicay® In combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age. Rapid Review Complete 13th March 2014
- Dolutegravir/lamivudine Dovato® For the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine. Rapid Review Complete 27th August 2019
- Dolutegravir/Rilpivirine Juluca® For the treatment of HIV-1 infection in adults who are virologically-suppressed on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. Rapid review complete 12th July 2018
- Doravirine Pifeltro® In combination with other antiretroviral medicinal products, for the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class. Rapid review complete 16th January 2019
- Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Delstrigo® For the treatment of adults infected with HIV-1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, lamivudine or tenofovir Rapid review complete 16th January 2019
24004 Dostarlimab Jemperli® Dostarlimab is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. Pre submission consultation scheduled 9th February 2024
21045 Dostarlimab Jemperli® Indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) recurrent or advanced endometrial cancer that has progressed on or following prior treatment with a platinum-containing regimen. NCPE Assessment Process Complete 27th March 2023
23052 Doxylamine/pyridoxine Cariban® Doxylamine/pyridoxine (Cariban®) is indicated for the symptomatic treatment of nausea and vomiting during pregnancy in adults who do not respond to conservative management. Rapid Review Complete 14th March 2024
- Doxylamine/pyridoxine Xonvea® For the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Rapid review complete 15th August 2019
- Dronedarone Multaq® __ Rapid review complete 12th January 2010
22073 Drospirenone/estetrol monohydrate Drovelis® Drospirenone/estetrol monohydrate is indicated for oral contraception. Rapid Review Complete 6th July 2023
- Dulaglutide Trulicity® As monotherapy for the treatment of adult patients with T2DM when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. Dulaglutide is indicated as an add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. Rapid review complete 29th April 2015
23047 Dupilumab Dupixent® Dupilumab (Dupixent®) is indicated for the treatment of adults and adolescents 12 years and older, weighing at least 40 kg, with eosinophilic oesophagitis (EoE) who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. Rapid Review Complete 7th September 2023
19056 Dupilumab Dupixent® For the treatment of moderate-to-severe atopic dermatitis in adolescents 12 years and older who are candidates for systemic therapy. Rapid review complete 17th January 2020
23043 Dupilumab Dupixent® Dupilumab (Dupixent®) is indicated for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Rapid Review Complete 24th August 2023
23044 Dupilumab Dupixent® Dupilumab (Dupixent®) is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. Rapid Review Complete 5th September 2023
21063 Dupilumab Dupixent® For adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance. Rapid review complete 14th March 2024
21035 Dupilumab Dupixent® For severe atopic dermatitis in children 6 to 11 years old who are candidates for systemic therapy. Rapid review complete 23rd September 2021
23042 Dupilumab Dupixent® Dupilumab is indicated for the treatment of severe atopic dermatitis in children aged 6 months to 6 years old who are candidates for systemic therapy. Rapid Review Complete 1st September 2023
23046 Dupilumab Dupixent® Dupilumab (Dupixent®) is indicated as an add-on therapy with intranasal corticosteroids, for the treatment of adults with severe chronic rhinosinusitis with nasal polyposis for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. Rapid Review Complete 5th September 2023
- Dupilumab Dupixent® For treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy. NCPE Assessment Process Complete 12th December 2019
- Durvalumab Imfinzi® For the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC)  in adults whose tumours express PD-L1 ≥1% on tumour cells and whose disease has not progressed following platinum-based chemo-radiation therapy (CRT). NCPE Assessment Process Complete 7th May 2020
21033 Durvalumab Imfinzi® In combination with etoposide and either carboplatin or cisplatin, for the first-line treatment of adult patients with extensive-stage small cell lung cancer. Rapid review complete 9th September 2021
23009 Durvalumab Imfinzi® Durvalumab in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adults with unresectable or metastatic biliary tract cancer. Full HTA submission received from Applicant 4th October 2023
- Eculizumab Soliris® For the treatment of paroxysmal nocturnal haemoglobinuria (PNH) in the Irish healthcare setting. Assessment process complete 14th October 2013
- Edoxaban Lixiana® For the prevention of stroke/SE in adults with NVAF and for the treatment/secondary prevention of DVT and PE in adults. Rapid review complete 10th July 2015
23026 Efgartigimod alfa Vyvgart® Efgartigimod alfa is indicated as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis who are anti-acetylcholine receptor antibody positive. Awaiting full HTA submission from Applicant 7th November 2023
22072 Eladocagene exuparvovec Upstaza® For the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype. __ 23rd December 2022
- Elbasvir 50mg/100mg grazoprevir Zepatier® For the treatment of genotypes 1 and 4 chronic HCV infection in patients with Child-Turcotte-Pugh score A (CTPA) Rapid review complete 13th October 2016
- Eliglustat Cerdelga® For the long-term treatment of adult patients with Gaucher disease type 1. Assessment process complete 25th April 2018
- Elosulfase alfa Vimzim® For the treatment of mucopolysaccharidosis, type IVA (Morquio A syndrome, MPS IVA) in patients of all ages. Assessment process complete 8th December 2016
23066 Elranatamab Elrexfio® Elranatamab (Elrexfio®) is indicated as monotherapy for the treatment of adult patients with relapsed, refractory multiple myeloma, who have received at least three prior therapies (including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody) and have demonstrated disease progression on the last therapy. Pre submission consultation scheduled 7th March 2024
- Eltrombopag Revolade® For the treatment of chronic immune thrombocytopenic purpura (ITP) Assessment process complete 4th November 2010
- Eltrombopag Revolade® For adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy Rapid review complete 14th February 2014
- Eltrombopag Revolade® For the treatment adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pre-treated and are unsuitable for haematopoietic stem cell transplantation. Assessment process complete 2nd March 2016
- Elvitegravir, Cobicistat, Emtricitabine, Tenofovir alafenamide Genvoya®  For the treatment of adults and adolescents infected with human immunodeficiency virus – 1 (HIV-1). Rapid review complete 6th January 2016